ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ivermectin

Also written as “ivermectin”, “Ivermectin cream” and “CD5024”.

Its studies are mostly in Rosacea · COVID-19 · Lice Infestations · Dermatitis, Atopic · Acne Vulgaris, led by 14 companies.

Drug pageIvermectin: every studyMany companies study it; this page follows only the 28 they lead. All 163 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 24, 201528 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Galderma Groupits history only60 open or runningphase 4since Nov 24, 2015Dec 14, 2011none ahead
Johnson & Johnsonits history only40 open or runningphase 3since Jan 8, 2009Jan 8, 2009none ahead
Topaz Pharmaceuticalsits history only40 open or runningphase 3since Feb 8, 2010Oct 1, 2009none ahead
Humanis Saglık Anonim Sirketiits history only20 open or runningphase 1since Sep 13, 2021Sep 13, 2021none ahead
MedinCell S.Aits history only20 open or runningphase 2since Mar 28, 2022Oct 26, 2020none ahead
Sun Pharmaceutical Industriesits history only20 open or runningphase 1since May 3, 2017May 3, 2017none ahead
Genuine Research Center, Egyptits history only10 open or runningphase 1since Apr 18, 2021Apr 18, 2021none ahead
Infectopharm Arzneimittel10 open or runningphase 3since Sep 28, 2021Sep 28, 2021none ahead
Insud Pharmaits history only10 open or runningphase 3since Aug 8, 2023Aug 8, 2023none ahead
Mayne Pharma International Ptyits history only10 open or runningphase 3since Oct 30, 2017Oct 30, 2017none ahead

Also a collaborator on its studies: Eva Pharma and bioRASI.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Infectopharm Arzneimittel only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 28, 2021First study: phase 3 study in COVID-19First studyNCT05060666 · 412 enrolled

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Glutamate-gated chloride channel modulator; Glutamate-gated chloride channel modulator”ChEMBL 37, by rule

Studies

The one study Infectopharm Arzneimittel leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05060666COVID-193UNKNOWNMar 2022412

How it is read

Names in the registry

  • “Ivermectin”, 4 entries
  • “ivermectin”, 4 entries
  • “Ivermectin cream”, 2 entries
  • “CD5024”, 2 entries
  • “0.5% Ivermectin Cream”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.